Puma Biotechnology, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed February 29, 2024. This is an annual report, not a standalone fourth-quarter report. Puma is a biopharmaceutical company whose commercial revenue is primarily from NERLYNX (neratinib); it is also developing alisertib.
Financial performance and position
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Total revenue | $235.6 million | $228.0 million |
| Product revenue, net | $203.1 million | $200.0 million |
| Royalty revenue | $32.5 million | $28.0 million |
| Income from operations | $32.6 million | $23.7 million |
| Net income | $21.6 million | $2,000 |
| Operating cash flow | $27.0 million | $(15.8) million |
| Cash, cash equivalents and marketable securities at year-end | $95.9 million | $81.1 million |
| Working capital at year-end | $56.8 million | $56.8 million |
- Total revenue increased 3.3%. Product revenue rose about 1.5%, as higher net selling price more than offset a 6.3% decline in bottles sold. Royalty revenue increased with sublicensee sales, including in China.
- Approximate gross margin was 73.4%, versus 75.8% in 2022; operating margin was 13.8%, versus 10.4%; net margin was 9.2%, versus approximately zero. Cost of sales rose to $62.7 million from $55.1 million.
- SG&A was essentially unchanged at $89.9 million. R&D declined 3.6% to $50.4 million, mainly due to reduced NERLYNX trial activity. Management expects R&D spending to increase significantly in 2024 as alisertib trials begin.
- Investing activities used $19.1 million, including a $12.5 million Pfizer commercial-milestone payment and net purchases of marketable securities. Cash and restricted cash increased $7.9 million; there were no financing cash flows in 2023.
- Outstanding Athyrium principal was $100.0 million; debt carrying value was approximately $99.7 million, including current and long-term portions. The effective interest rate was 12.99%. Quarterly principal payments begin June 30, 2024; the notes mature July 2026 and are secured by substantially all company assets.
Changes, outlook and material matters
- Profitability improved substantially from near break-even in 2022. The comparison reflects, among other items, a $12.5 million legal verdict expense in 2022 that was not recorded in 2023. Interest expense increased to $13.3 million from $11.6 million, partly due to higher rates and imputed interest on the remaining legal settlement payment.
- Management said existing cash, marketable securities and anticipated product and sublicense proceeds are expected to fund operating and capital needs for at least one year after filing. This depends on assumptions; the company warns that lower revenue or higher development spending could affect liquidity and compliance with debt covenants. No specific revenue or earnings guidance was provided.
- Puma initiated the Phase II ALISCA-Lung1 alisertib trial in extensive-stage small cell lung cancer in February 2024, after year-end. It plans to start the ALISCA-Breast1 Phase II trial in the second half of 2024. These are plans, not reported trial outcomes.
- The company reported $7.7 million accrued for the Eshelman settlement, with the final $8.0 million payment due on or before November 1, 2024. Its malpractice suit against former counsel was awaiting a ruling on dismissal motions after a February 2024 hearing.
- China approved an Acebright generic neratinib application in September 2023; Puma filed a separate infringement suit in December 2023. Other China generic proceedings remain relevant. A U.S. patent-infringement case against AstraZeneca was scheduled for jury trial on May 13, 2024.
- Revenue is concentrated: four customers represented approximately 31.4%, 17.2%, 15.2% and 11.9% of 2023 product revenue. Sublicensee royalties were $32.5 million, or 14% of total revenue. A $0.9 million credit-loss provision related to royalties receivable was recorded.
- Puma reported an accumulated deficit of $1.345 billion despite net income in 2023 and 2022. It identifies reliance on one commercial product, competition, NERLYNX tolerability and adoption, sublicensee execution, third-party manufacturing, clinical-development uncertainty, intellectual-property challenges and debt covenants as material risks.
- KPMG issued unqualified opinions on the financial statements and internal control over financial reporting. Management reported effective disclosure controls and internal controls as of December 31, 2023.
Important facts for investors to verify
- Whether NERLYNX sales and pricing can offset declining unit volume, and whether the concentrated customer base remains stable.
- Whether Chinese generic competition, patent disputes and sublicensee performance affect NERLYNX sales and royalties.
- Cash generation, upcoming Athyrium principal and interest payments, and continued compliance with minimum cash and revenue covenants.
- Timing, costs, enrollment and results of the alisertib trials, including whether the planned breast cancer trial begins in the second half of 2024.
- The status and potential financial effect of the AstraZeneca litigation, remaining Eshelman settlement payment and malpractice action.